PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus

Wiener Klinische Wochenschrift

Volumn 117, Issue 19-20, 2005, Pages 707-710

  Funk, Marion ^a   Endler, Georg ^a   Exner, Markus ^a   Marculescu, Rodrig ^a   Endler, Lukas ^a   Abrahamian, Heidemarie ^b   Mauler, Harald ^b   Grimm, Angelika ^b   Raith, Marianne ^a   Mannhalter, Christine ^a   Prager, Rudolf ^b   Irsigler, Karl ^c   Wagner, Oswald F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c L Boltzmann Res Inst Phys Diagn   (Austria)

Author keywords

Microvascular disease; PAI 1; Polymorphism; Type 2 diabetes mellitus

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALLELE; ARTICLE; AUSTRIA; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DNA POLYMORPHISM; EXTRACELLULAR MATRIX; FEMALE; FIBRINOLYSIS; GENE INSERTION; GENETIC RISK; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROMOTER REGION; PROTEINURIA;

AGED; ARYL HYDROCARBON HYDROXYLASES; AUSTRIA; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DNA MUTATIONAL ANALYSIS; DNA TRANSPOSABLE ELEMENTS; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 28344433020     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0425-9     Document Type: Article

References (15)

1. Keen H LE, Russell D, Miki E, Bennett PH, Lu M (2001) The appearance of retinopathy and progression to proliferative retinopathy: the WHO multinational study of vascular disease in diabetes. Diabetologica 44: S22-S30
2. Abrahamian H HB, Gurdet C, Willinger C, Zaruba E, Irsigler K (1994) Insulin-dependent diabetes mellitus: "EURODIAB IDDM Complications Study" - results from the Vienna center. Wien Klin Wochenschr 106: 136-140
3. Tsilibary EC (2003) Microvascular basement membranes in diabetes mellitus. J Pathol 200: 537-546
4. Chavers BM, Mauer SM, Ramsay RC, Steffes MW (1994) Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 43: 441-446
5. Paueksakon P, Revelo MP, Ma LJ, Marcantoni C, Fogo AB (2002) Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 61: 2142-2148
6. Tarnow L, Stehouwer CD, Emeis JJ, Poirier O, Cambien F, Hansen BV, et al (2000) Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant 15: 625-630
7. Nakamura T, Tanaka N, Higuma N, Kazama T, Kobayashi I, Yokota S (1996) The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy. J Am Soc Nephrol 7: 2434-2444
8. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ (1997) Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 20: 1304-1309
9. Margaglione M, Cappucci G, d'Addedda M, Colaizzo D, Giuliani N, Vecchione G, et al (1998) PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 18: 562-567
10. Richard JL, Sultan A, Daures JP, Vannereau D, Parer-Richard C (2002) Diagnosis of diabetes mellitus and intermediate glucose abnormalities in obese patients based on ADA (1997) and WHO (1985) criteria. Diabet Med 19: 292-299
11. Sjolie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, et al (1997) Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 104: 252-260
12. Endler G LW, Exner M, Mitterbauer G, Haring D, Mannhalter C (2000) The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 110: 469-471
13. Geishofer G BA, Muller M, Zohrer B, Resch B, Muller W, Faber J, Finn A, Endler G, Mannhalter C, Zenz W; the Central European Meningococcal Genetic Study Group (2005) 4G/5G promoter polymorphism in the plasminogen-activator- inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr [Ahead of print]
14. Santos KG TB, Schneider J, Souto K, Roisenberg I (2003) Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract 61: 133-136
15. Mansfield MW SM, Carter AM, Grant PJ (1994) Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 71: 731-736